FDA transfers stem cell wound care review away from medical device arm

August 14, 2013 by Arezu Sarvestani

Effective immediately, the FDA transfers review of certain live-cell wound care therapies from the Center for Devices & Radiological Health to the Center for Biologics Evaluation & Research.

FDA transfers certain wound care review responsiblities within agency

The FDA is shifting some of its wound care review responsibilities away from the Center for Devices & Radiological Health, handing them instead to the Center for Biologics Evaluation & Research.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp